Effectiveness of gemcitabine as secondline chemotherapy in non-small cell lung cancer;Küçük hücreli dışı akciǧer kanserinde ikinci basamak kemoterapi olarak gemsitabinin etkinliǧi

Tuberkuloz ve Toraks

Volumn 56, Issue 1, 2008, Pages 74-80

  Çok, Gürsel ^a   Göksel, Tuncay ^a   Soyer, Serdar ^a   Aysan, Tülin ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Gemcitabine; Non small cell lung cancer; Second line chemotherapy

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

ADULT; ARTICLE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 63449129795     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Parkin GM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
2. Fidaner C, Eser SY, Parkin DM. Incidence in Izmir in 1993-1994: First results from Izmir Cancer Registry. Eur J Cancer 2001; 37: 83-92.
3. NSCLC Collaborative Group. Chemotherapy in nonsmall cell lung cancer; a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899-909.
4. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology. Treatment of unresectable nonsmall cell lung cancer guideline: Update 2003. J Clin Oncol 2004; 22: 1-24.
5. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
6. Fossella F, DeVore R, Kerr R, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced NSCLC previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18: 2354-2362.
7. Manegold C, Bergman B, Chemaissani A, et al. Single agent gemcitabine versus cisplatin etoposide: Early results of a randomized phase II study in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 1997; 22: 243-250.
8. Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: A phase II trial. Semin Oncol 1998; Suppl 9: 23-26.
9. Sculier JP, Lafitte JJ, Berghmans T, et al. A phase II trial testing gemcitabine as second line chemotherapy for non-small cell lung cancer. Lung Cancer 2000; 29: 67-73.
10. Gillenwater HH, Tynan M, Natoli S, et al. Second line gemcitabine in refractory stage IV non-small cell lung cancer a phase II trial. Clin Lung Cancer 2000; 2: 133-138.
11. Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced non-small cell lung cancer: A phase II trial. J Clin Oncol 1999; 17: 2081-2085.
12. Sözbilen M, Göksel T, Akkoçlu A. Lung and pleural malignancy, patient database program. Izmir, Publication of Turkish Thoracic Society, Izmir Branch 1997.
13. Reddy GR, Gandara DR, Edelman MJ, et al. Gemcitabine in platinum treated non-small cell lung cancer. Proc Am Soc Clin Oncol 1999; 18: 521.
14. Van Putten JWG, Baas P, Codrington H, et al. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced nonsmall-cell lung cancer. Lung Cancer 2001; 33: 289-298.
15. Cho KS, Song YB, Choi IS, et al. A Phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer. Jpn J Clin Oncol 2006; 36: 50-54.
16. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum refractory nonsmall cell lung cancer. J Clin Oncol 1995; 13: 645-651.
17. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best-supportive care in patients with NSCLC previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
18. Alexopoulos K, Kouroussis C, Androulakis N, et al. Docetaxel and granulocyte colony-stimulating factor in patients with advanced NSCLC previously treated with platinum- based chemotherapy: A multicenter phase II trial. Cancer Chemother Pharmacol 1999; 43: 257-262.
19. Murphy WK, Win RJ, Huber M, et al. Phase II study of Taxol in patients with NSCLC who have failed platinumcontaining chemotherapy. Proc Am Soc Clin Oncol 1994; 13: 363.
20. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995; 13: 1609-1614.
21. Pronzato P, Landucci M, Vaira F. Failure of vinorelbine to produce responses in pre-treated NSCLC patients. Anticancer Res 1994; 14: 1413-1416.
22. Rinaldi M, Della Giulia M, Venturo I. Vinorelbine as single agent in the treatment of advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1994; 13: 360.
23. Santoro A, Maiorino L, Santoro M. Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer. Lung Cancer 1994; 11: 130.